Published in Ann Oncol on August 12, 2009
Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States: 1973 to 2010. Chest (2015) 0.86
The role of palliative chemotherapy in hospitalized patients. Curr Oncol (2014) 0.81
Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer. Hosp Pharm (2015) 0.75
Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort. Can Respir J (2013) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1996) 3.55
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
Transformation of alveolar type 2 cells to type 1 cells following exposure to NO2. Exp Mol Pathol (1975) 3.07
Validity of sexual histories in a prospective study of male sexual contacts of men with AIDS or an AIDS-related condition. Am J Epidemiol (1988) 2.81
Renewal of alveolar epithelium in the rat following exposure to NO2. Am J Pathol (1973) 2.80
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52
Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48
Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol (2000) 2.46
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol (2006) 2.38
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax (2004) 2.22
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Empirical equation that can be used to determine genetic map distances from tetrad data. Mol Cell Biol (1983) 2.16
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg (2004) 2.14
Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling. Nat Biotechnol (1999) 2.09
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med (2000) 2.07
Risk factors for HIV infection in male sexual contacts of men with AIDS or an AIDS-related condition. Am J Epidemiol (1988) 2.05
Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol (2005) 2.04
Assessing the FDA guidelines for ordering dental radiographs. J Am Dent Assoc (1995) 2.02
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Pressure waves in so-called low-pressure hydrocephalus. Lancet (1972) 1.94
MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol (2007) 1.94
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) (1996) 1.93
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc Natl Acad Sci U S A (1999) 1.87
Renewal of the terminal bronchiolar epithelium in the rat following exposure to NO2 or O3. Lab Invest (1976) 1.85
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77
Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol (1992) 1.77
Evidence of a locus for orofacial clefting on human chromosome 6p24 and STS content map of the region. Hum Mol Genet (1995) 1.75
Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol (2009) 1.68
Cancer incidence among Canadian kidney transplant recipients. Am J Transplant (2007) 1.66
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
The reliability of sexual histories in AIDS-related research: evaluation of an interview-administered questionnaire. Can J Public Health (1987) 1.60
Regulation of touch receptor differentiation by the Caenorhabditis elegans mec-3 and unc-86 genes. Development (1998) 1.57
Imaging of the temporomandibular joint: a position paper of the American Academy of Oral and Maxillofacial Radiology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1997) 1.53
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer (1995) 1.52
Retracted A cytosolic catalase is needed to extend adult lifespan in C. elegans daf-C and clk-1 mutants. Nature (1999) 1.51
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol (1984) 1.51
A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. Gen Pharmacol (1978) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther (2001) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
The antinociceptive activity of meptazinol depends on both opiate and cholinergic mechanisms. Br J Pharmacol (1983) 1.44
Early response of lungs to low levels of nitrogen dioxide. Light and electron microscopy. Arch Environ Health (1972) 1.44
Subunit composition of pro-phenol oxidase from Manduca sexta: molecular cloning of subunit ProPO-P1. Insect Biochem Mol Biol (1997) 1.44
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer (2006) 1.44
A dental x-ray validation study. Comparison of information from patient interviews and dental charts. Am J Epidemiol (1985) 1.42
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol (1989) 1.42
Lymphoma of the gastrointestinal tract. Semin Oncol (1999) 1.41
Efficacy of TMJ radiographs in terms of expected versus actual findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 1.40
Sexual behaviour changes in a cohort of male sexual contacts of men with HIV disease: a three-year overview. Can J Public Health (1991) 1.40
Construction and implantation of a cannula system for repeated injections into localized regions of the rat brain. J Pharm Pharmacol (1975) 1.39
Mitral annular tissue velocity in the diagnosis of coronary artery disease. Eur Rev Med Pharmacol Sci (2014) 1.39
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med (1987) 1.38
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol (R Coll Radiol) (1997) 1.38
Can an electric field induce an antiferroelectric phase out of a ferroelectric phase? Phys Rev Lett (2010) 1.38
An improved microassay for Plasmodium falciparum cytoadherence using stable transformants of Chinese hamster ovary cells expressing CD36 or intercellular adhesion molecule-1. Am J Trop Med Hyg (1993) 1.36
Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther (2001) 1.36
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34
Regulation of Caenorhabditis elegans degenerin proteins by a putative extracellular domain. Curr Biol (1995) 1.34
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.33
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer (1996) 1.32
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31
Three-dimensional solid-state NMR spectroscopy is essential for resolution of resonances from in-plane residues in uniformly (15)N-labeled helical membrane proteins in oriented lipid bilayers. J Magn Reson (2000) 1.31
Studies of case-finding for pulmonary tuberculosis in outpatients at 4 district hospitals in Kenya. Tubercle (1985) 1.31
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol (1985) 1.30
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach. J Med Chem (2000) 1.28
Extragonadal germ cell tumors. A 14-year Toronto experience. Cancer (1994) 1.27
ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1994) 1.27
5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Br J Cancer (1976) 1.27
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer (2007) 1.27
Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression. Am J Physiol Gastrointest Liver Physiol (2011) 1.27
Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology (1999) 1.26